SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc.
(Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings, today announced
that management will participate in a fireside chat at the 2024
Maxim Healthcare Virtual Summit and will be available for 1x1
meetings with registered investors. The summit is being held on
October 15-17, 2024.
Event: 2024 Maxim Healthcare Virtual Summit
Date: October 16,
2024
Time: 3:00 PM ET / 12:00
Noon PT
Webcast link: 2024 Maxim Healthcare Virtual Summit
About Talphera, Inc.
Talphera, Inc. is a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings. Talphera's lead product candidate, Niyad™ is a
lyophilized formulation of nafamostat and is currently being
studied under an investigational device exemption (IDE) as an
anticoagulant for the extracorporeal circuit, and has received
Breakthrough Device Designation status from the U.S. Food and Drug
Administration (FDA).
This release is intended for investors only. For additional
information about Talphera, please visit www.talphera.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/talphera-to-participate-in-fireside-chat-at-the-2024-maxim-healthcare-virtual-summit-302270671.html
SOURCE Talphera, Inc.
